Amended and Restated Collaboration and Commercialization Agreement with Ascensia, which amended and restated the 2020 Commercialization Agreement and terminated Ascensia's U.S. marketing rights for Eversense
| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Timothy T. Goodnow
Also a director
President and CEO
Title from the Form 4 dated Jun 15, 2026
|
64 | Not stated | $3,347,959 | |
|
Frederick (“Rick”) Sullivan
Chief Financial Officer
|
42 |
Since 2022
4 years
|
$1,392,599 | |
|
Mukul Jain
Chief Operating Officer
|
53 |
Since 2017
9 years
|
$1,945,166 | |
|
Kenneth L. Horton
General Counsel and Corporate Development Advisor
|
59 |
Since 2017
9 years
|
Not reported | |
|
Brian Hansen
Also a director
Chief Commercial Officer
Title from the Form 4 dated Jun 15, 2026
|
58 | Not stated | Not reported | |
|
Francine R. Kaufman
Also a director
Chief Medical Officer
Title from the Form 4 dated Jun 15, 2026
|
75 | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Amended and Restated Collaboration and Commercialization Agreement with Ascensia, which amended and restated the 2020 Commercialization Agreement and terminated Ascensia's U.S. marketing rights for Eversense
Master asset purchase agreement under which the Company acquired Ascensia's assets related to Eversense marketing and distribution in the United States, effective January 1, 2026
Net revenue from the Company's distribution arrangement with Ascensia as a share of total net revenues
Commissions due from the Company to Ascensia at year end
Amount due from Ascensia to the Company at year end
Purchases of medical supplies from Ascensia for clinical trials
Loading...